An in vitro redox adaptation model for metastatic prostate cancer: Establishing, characterizing and Cabazitaxel response evaluating. (14th July 2022)
- Record Type:
- Journal Article
- Title:
- An in vitro redox adaptation model for metastatic prostate cancer: Establishing, characterizing and Cabazitaxel response evaluating. (14th July 2022)
- Main Title:
- An in vitro redox adaptation model for metastatic prostate cancer: Establishing, characterizing and Cabazitaxel response evaluating
- Authors:
- Eryilmaz, Isil Ezgi
Egeli, Unal
Cecener, Gulsah - Abstract:
- Abstract: Little is known about the redox‐adapted cancer cells for understanding their pharmacologically targetable features and chemotherapeutic responses. Thus, we present the first in vitro redox adaptation model for metastatic prostate cancer (mPC), LNCaP‐hydrogen peroxide resistant (LNCaP‐HPR), with enhanced oxidative stress resistance accompanying poor Cabazitaxel response. After establishing, the cells were characterized by comparing the viability, death, oxidative stress, total glutathione (GSH) levels and the mRNA and protein levels of the redox‐sensitive transcription factors responsible for the adaptation, Nrf‐2, NF‐κB and HIF‐1α. Then, the apoptotic effect of Cabazitaxel was evaluated in LNCaP mPC, LNCaP‐HPR and C4‐2 metastatic castration‐resistant (mCRPC) cells. In response to H2 O2, viability, oxidative stress and the total GSH levels of LNCaP‐HPR cells have confirmed the oxidative stress resistance. Nrf‐2, NF‐κB and HIF‐1α were upregulated in LNCaP‐HPR cells, not in LNCaP, confirming that resistant cells were much less affected by exogenous oxidative stress. Unlike LNCaP, LNCaP‐HPR cells were less sensitive to Cabazitaxel, as closer to the response of C4‐2 mCRPC cells, indicating that redox adaptation decreased Cabazitaxel response. This is the first evaluated association between redox adaptation and poor Cabazitaxel response, suggesting that in vitro Cabazitaxel efficiency is affected by PC cells' endogenous oxidative stress tolerance.
- Is Part Of:
- Clinical and experimental pharmacology and physiology. Volume 49:Number 10(2022)
- Journal:
- Clinical and experimental pharmacology and physiology
- Issue:
- Volume 49:Number 10(2022)
- Issue Display:
- Volume 49, Issue 10 (2022)
- Year:
- 2022
- Volume:
- 49
- Issue:
- 10
- Issue Sort Value:
- 2022-0049-0010-0000
- Page Start:
- 1094
- Page End:
- 1104
- Publication Date:
- 2022-07-14
- Subjects:
- Cabazitaxel -- hydrogen peroxide -- oxidative stress resistance -- prostate cancer -- redox adaptation
Clinical pharmacology -- Periodicals
Pharmacology, Experimental -- Periodicals
Physiology, Experimental -- Periodicals
Physiology, Pathological -- Periodicals
615.1 - Journal URLs:
- http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=cep ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/1440-1681.13694 ↗
- Languages:
- English
- ISSNs:
- 0305-1870
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.252000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 23302.xml